RenovoRx’s TAMP platform is a minimally invasive procedure that delivers therapeutic agents directly to tumors through the blood vessels, allowing for targeted treatment. This approach overcomes the limitations of traditional systemic delivery methods, which may not effectively reach difficult-to-access tumors.
Imugene’s CF33 oncolytic virus therapy is designed to selectively infect and kill cancer cells while sparing healthy cells. By combining this targeted therapy with RenovoRx’s TAMP platform, the two companies aim to enhance the efficacy and precision of treatment for patients with challenging-to-treat cancers.
Under the collaboration agreement, RenovoRx will provide its expertise in trans-arterial drug delivery systems, while Imugene will contribute its knowledge in developing oncolytic viruses. The companies will work together to optimize the delivery of CF33 using RenovoRx’s TAMP technology.
The collaboration aims to address the un